logo
How one wellness habit redeemed a life of addiction

How one wellness habit redeemed a life of addiction

Perth Now20-06-2025
At 23, John Ogilvie hit rock bottom.
After years of substance abuse, he made the painful decision to end his life because he felt like a burden to everyone around him.
Thankfully he survived and that moment became a turning point.
Mr Ogilvie slowly rebuilt his life. After exploring spirituality, he eventually took a leap of faith into a new path and says he's never looked back.Today, he's in a much better place and lives and breathes yoga.
But it was not always this way.
The now 68-year-old was only 12 when he first turned to alcohol.
As a teen, he felt like he didn't fit in. Drinking made him feel different, it was his way of finding connection and a sense of belonging.
It was about five years later when Mr Ogilvie went from taking speed, acid and other hallucinogens to dabbling with heroin.
This sparked the beginning of a relentless cycle that had him in its grip for a decade.
"From 17 to 27, I was swinging between using narcotics obsessively to trying to get off narcotics, particularly heroin," he says.
"It became a merry-go-round ... a very unhappy life."
Hitting a wall of darkness, Mr Ogilvie began to think there was "no purpose to live".
"I was lost and in a deep depression," he says.
"I had buried myself in debt. I was at a physical low and not capable of working. I couldn't see anywhere else to turn to other than to just end my life."
Despite his intentions, Mr Ogilvie woke days after falling into a coma.
Some time later, he found himself in a detox centre and speaking with a priest who told him he'd survived for a reason.
"Maybe there was a purpose in my life," he remembers thinking.
It was at Victoria's Pleasant View Centre that he was first introduced to yoga.
He recalls one night in the facility, a staff member photocopying sheets of yoga poses. He he went on to practice them daily.
Although subsequently relapsing, Mr Ogilvie eventually entered another residential rehab facility that changed everything for him.
The Buttery, in NSW's Northern Rivers region, supports people dealing with alcohol and drug addiction as well as mental health challenges, helping them recover and rebuild their lives.
During his five-month stay in 1986, everything finally began falling into place.
He credits a combination of the spiritual guidelines of the centre's program and the practices and philosophies of yoga for his transformation.
It was during this time he began to truly heal and discover his purpose.
"The Buttery really taught (me) life skills I hadn't developed in adulthood like how to clean the house, cook meals and socialise in a sober way with other people," Mr Ogilvie says.
"The 12-step program gives people tools to continue with their recovery after they leave there."
The year before his stay, the centre was referenced in Paul Kelly's hit To Her Door, which would eventually go seven times platinum and ranks among the top Australian songs of all time.
Chief executive Leone Crayden says The Buttery has helped thousands in residential rehabilitation and 20,000 in its community outreach programs over its 50-year history.
"Many people stay within the area and this assists in nurturing a special community of people who believe in sober living and giving back to the community," she tells AAP.
"Our graduates are entrepreneurs, lawyers, clinical psychologists, Aboriginal artists and mentors to many people seeking recovery."
Ms Crayden says the centre is also home to a community and lived experience program.
"The counsellors, case managers, co-ordinators and managers of the rehabilitation program have been through The Buttery themselves and gone on to obtain qualifications in social work, nursing and counselling, and are valued for their lived experience."
After completing his time there, Mr Ogilvie moved to Sydney and obsessively attended classes to become a yoga instructor.
Soon after, he found himself back up north where he opened his own studio, the Byron Yoga Centre.
It specialises in Purna yoga, a holistic practice combining physical posture with philosophy, meditation, breathwork and ethical living.
The centre also offers eco-friendly accommodation and a mindful vegetarian diet.
Mr Ogilvie remains connected to The Buttery, supporting others on their journey.
"Yoga has so much depth and interest to it and that's where my passion is," he says.
"People can come and I can give them skills that can really help turn their life around.
It's jus not for recovering addicts but also big-time CEOs who are stressed and feeling unhealthy in their life.
"Yoga is really for everybody."
It sounds simple but Mr Ogilvie remains hopeful for the future and vision he's built.
As living proof yoga is truly life-changing, he wants to continue teaching and promoting it for everyone.
Lifeline 13 11 14
beyondblue 1300 22 4636
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant
Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant

Sydney Morning Herald

timean hour ago

  • Sydney Morning Herald

Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant

To get an idea of where the real financial gravity sits within the Australian investing universe, CSL's market valuation plunge on Tuesday exceeded the entire $17 billion value of Qantas Airways with a billion or two to spare. It would be unfair to just blame this huge 15 per cent stock slump on its battles with the Trump administration. The biopharmaceutical giant has other challenges that were revealed on Tuesday with its full-year financial results and massive cost-cutting. But that should only add to the alarm for investors who may have noticed its outlook statement included the words: 'This guidance assumes no impact from pharmaceutical sector tariffs.' For the uninitiated, CSL's business is dominated by blood plasma products, but includes iron-deficiency-type treatments as well as vaccines. The vaccines company, Seqirus, will soon be spun off into a separately listed business. CSL chief executive Paul McKenzie put a brave face on Trump's threats to put tariffs up to 250 per cent on pharmaceuticals. This could affect $2 billion worth of Australian exports and the single biggest impact is expected to be on CSL's US exports, which are dominated by plasma products. Loading McKenzie pointed out to investors and analysts that most of the company's US business is sourced there, but the repeated questions from his audience say plenty about the market's nervousness. Especially when one question queried whether the Melbourne-based CSL was re-domiciling to the US. 'I'm not quite sure I relate to the re-domicile point. But just in general for tariffs, if you look at our plasma-derived products – as required from [US] regulatory, the plasma is sourced all in the US,' McKenzie said.

Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant
Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant

The Age

timean hour ago

  • The Age

Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant

To get an idea of where the real financial gravity sits within the Australian investing universe, CSL's market valuation plunge on Tuesday exceeded the entire $17 billion value of Qantas Airways with a billion or two to spare. It would be unfair to just blame this huge 15 per cent stock slump on its battles with the Trump administration. The biopharmaceutical giant has other challenges that were revealed on Tuesday with its full-year financial results and massive cost-cutting. But that should only add to the alarm for investors who may have noticed its outlook statement included the words: 'This guidance assumes no impact from pharmaceutical sector tariffs.' For the uninitiated, CSL's business is dominated by blood plasma products, but includes iron-deficiency-type treatments as well as vaccines. The vaccines company, Seqirus, will soon be spun off into a separately listed business. CSL chief executive Paul McKenzie put a brave face on Trump's threats to put tariffs up to 250 per cent on pharmaceuticals. This could affect $2 billion worth of Australian exports and the single biggest impact is expected to be on CSL's US exports, which are dominated by plasma products. Loading McKenzie pointed out to investors and analysts that most of the company's US business is sourced there, but the repeated questions from his audience say plenty about the market's nervousness. Especially when one question queried whether the Melbourne-based CSL was re-domiciling to the US. 'I'm not quite sure I relate to the re-domicile point. But just in general for tariffs, if you look at our plasma-derived products – as required from [US] regulatory, the plasma is sourced all in the US,' McKenzie said.

Biotech giant CSL to cut 3000 jobs and spin-off vaccine arm as it cuts costs
Biotech giant CSL to cut 3000 jobs and spin-off vaccine arm as it cuts costs

7NEWS

time2 hours ago

  • 7NEWS

Biotech giant CSL to cut 3000 jobs and spin-off vaccine arm as it cuts costs

Australian pharmaceutical giant CSL will cut as many as 3000 jobs and spin-off its flu vaccine arm into a separate business in a bid to shave $500 million from its bottom line. The biotechnology firm announced the shake-up at its annual financial results call on Tuesday, where its chief executive dismissed concerns about US tariffs, but warned about the impact of falling vaccination levels. The company, which is the third largest in Australia, also revealed its revenue rose by 5 per cent during the last financial year and its profit after tax grew by 14 per cent to $US3 billion ($A4.6 billion). Despite its rising profit, CSL chief executive Paul McKenzie told investors the global pharmaceutical market had become a volatile environment, and the company would need to adapt to meet its financial goals and simplify operations. Cost reductions would include cutting up to 15 per cent of its workforce worldwide over the next three years, and closing 22 US plasma centres over the next 12 months. 'We are pleased with this performance, but we know we must rapidly adapt to position ourselves well into the next decade in a constantly evolving operating environment,' Mr McKenzie said. 'We will target more than half a billion US dollars in savings by the end of fiscal year '28.' The company would also seek to 'de-merge' its flu vaccination arm, Seqirus, as part of the shake-up, to become a separate ASX-listed company chaired by former CSL Seqirus president Gordon Naylor. The move would come at a challenging time for flu vaccinations worldwide after low rates of take-up in some countries, Mr McKenzie said, but with signs that could improve. 'We view the softness in the US seasonal category as highly irrational based on the vaccine risk-reward profiles and the scale of disease burdens which this year reached a 15-year high,' he said. 'In the US... we are encouraged by the recent positive universal recommendation by (the Advisory Committee on Immunisation Practices), a clear sign that influenza is not going away and it still has severe impact on public health.' Potential pharmaceutical tariffs floated by US President Donald Trump were also unlikely to affect CSL, Mr McKenzie told investors, due to its operations in the US. Trump threatened to impose tariffs of up to 250 per cent on drug imports from Australia earlier this month, though has yet to confirm details or a timeline for the plan. Total revenue for CSL rose to $US15.5 billion during the 2025 financial year, and the company forecasts revenue to grow between four and five per cent over the 2026 financial year. The company will pay a final dividend of $US1.62 to shareholders, up by 12 per cent.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store